Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2012 2
2013 1
2015 2
2016 8
2017 9
2018 13
2019 17
2020 13
2021 24
2022 20
2023 10
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 35701217

105 results

Results by year

Filters applied: . Clear all
Page 1
177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy.
Banerjee SR, Kumar V, Lisok A, Chen J, Minn I, Brummet M, Boinapally S, Cole M, Ngen E, Wharram B, Brayton C, Hobbs RF, Pomper MG. Banerjee SR, et al. Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2545-2557. doi: 10.1007/s00259-019-04434-0. Epub 2019 Aug 10. Eur J Nucl Med Mol Imaging. 2019. PMID: 31399803 Free PMC article.
A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
Leibowitz R, Davidson T, Gadot M, Aharon M, Malki A, Levartovsky M, Oedegaard C, Saad A, Sandler I, Ben-Haim S, Domachevsky L, Berger R. Leibowitz R, et al. Oncologist. 2020 Sep;25(9):787-792. doi: 10.1634/theoncologist.2020-0100. Epub 2020 Jun 10. Oncologist. 2020. PMID: 32430954 Free PMC article.
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. Hofman MS, et al. Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8. Lancet Oncol. 2018. PMID: 29752180 Clinical Trial.
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
Vlachostergios PJ, Niaz MJ, Skafida M, Mosallaie SA, Thomas C, Christos PJ, Osborne JR, Molina AM, Nanus DM, Bander NH, Tagawa ST. Vlachostergios PJ, et al. Prostate. 2021 Apr;81(5):279-285. doi: 10.1002/pros.24104. Epub 2021 Jan 19. Prostate. 2021. PMID: 33465252 Free PMC article. Clinical Trial.
Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program: A case in Lutetium-177 prostate-specific membrane antigen (PSMA) therapy.
Zoberi JE, Garcia-Ramirez J, Luechtefeld D, Maughan NM, Amurao M, Oyama R, Baumann BC, Gay HA, Michalski JM. Zoberi JE, et al. J Appl Clin Med Phys. 2023 Apr;24(4):e13899. doi: 10.1002/acm2.13899. Epub 2023 Jan 13. J Appl Clin Med Phys. 2023. PMID: 36637862 Free PMC article.
105 results